Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AWH

AWH - Aspira Women's Health Inc. Stock Price, Fair Value and News

4.41USD-0.25 (-5.36%)Market Closed
Watchlist

Market Summary

USD4.41-0.25
Market Closed
-5.36%

AWH Stock Price

View Fullscreen

AWH RSI Chart

AWH Valuation

Market Cap

45.6M

Price/Earnings (Trailing)

-2.51

Price/Sales (Trailing)

4.97

EV/EBITDA

-2.41

Price/Free Cashflow

-7.44

AWH Price/Sales (Trailing)

AWH Profitability

EBT Margin

-208.29%

Return on Equity

-3.54%

Return on Assets

-210.02%

Free Cashflow Yield

-13.45%

AWH Fundamentals

AWH Revenue

Revenue (TTM)

9.2M

Rev. Growth (Yr)

7%

Rev. Growth (Qtr)

-11%

AWH Earnings

Earnings (TTM)

-18.2M

Earnings Growth (Yr)

39.53%

Earnings Growth (Qtr)

-103.11%

Breaking Down AWH Revenue

Last 7 days

0.4%

Last 30 days

-1.4%

Last 90 days

48.6%

Trailing 12 Months

-37.1%

How does AWH drawdown profile look like?

AWH Financial Health

Current Ratio

1.47

Debt/Equity

0

Debt/Cashflow

-4.97

AWH Investor Care

Shares Dilution (1Y)

24.59%

Diluted EPS (TTM)

-2.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20238.6M9.0M9.2M0
20227.2M7.5M7.9M8.2M
20214.9M6.0M6.4M6.8M
20205.0M4.6M4.5M4.7M
20193.2M3.6M4.2M4.5M
20181.5M2.0M2.5M3.1M
2017477.0K632.0K787.0K942.0K
20161.7M1.9M2.2M322.0K
20153.2M3.4M3.4M2.2M
20142.5M2.5M2.5M2.5M
20132.1M2.1M2.1M2.6M
20121.8M1.8M1.8M2.1M
20111.4M1.5M1.7M1.9M
20100001.2M

Tracking the Latest Insider Buys and Sells of Aspira Women's Health Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 26, 2024
sandford nicole
bought
-
-
2,400
president & ceo
Dec 06, 2023
merchant minh hoang
sold
-3,302
3.37
-980
secretary & general counsel
Dec 06, 2023
sandford nicole
bought
16,800
3.36
5,000
president & ceo
Nov 17, 2023
merchant minh hoang
acquired
-
-
10,000
secretary & general counsel
Nov 17, 2023
hombeck torsten
acquired
-
-
30,000
chief financial officer
Sep 08, 2023
hombeck torsten
bought
9,657
4.3
2,246
chief financial officer
Aug 29, 2023
sandford nicole
acquired
-
-
26,367
president and ceo
Aug 29, 2023
sandford nicole
acquired
-
-
26,467
president & ceo
Aug 28, 2023
jordan veronica gh
acquired
-
-
7,045
-
Aug 28, 2023
fralick celeste rachelle
acquired
-
-
13,252
-

1–10 of 50

Which funds bought or sold AWH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
BARCLAYS PLC
sold off
-100
-
-
-%
Feb 15, 2024
TOWNSQUARE CAPITAL LLC
sold off
-100
-197,297
-
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-61,661
-
-%
Feb 14, 2024
Royal Bank of Canada
new
-
38,000
38,000
-%
Feb 14, 2024
VANGUARD GROUP INC
added
7.2
-180,341
799,708
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
sold off
-100
-65,156
-
-%
Feb 14, 2024
Northeast Financial Consultants Inc
unchanged
-
-29,998
95,619
-%
Feb 14, 2024
Squarepoint Ops LLC
new
-
62,689
62,689
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
63.26
23,256
119,066
-%

1–10 of 36

Are Funds Buying or Selling AWH?

Are funds buying AWH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AWH
No. of Funds

Unveiling Aspira Women's Health Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Dec 26, 2023
schultz eric adam
263%
543,998
SC 13G
Jul 26, 2023
schuler jack w
18.7%
1,883,656
SC 13D/A
Feb 15, 2023
seamark capital lp
5.1%
-
SC 13G/A
Aug 29, 2022
schuler jack w
20.8%
25,885,120
SC 13D/A
Feb 16, 2022
seamark capital lp
5.0%
-
SC 13G/A
Feb 14, 2022
drysdale robert h
-
0
SC 13G
Jan 13, 2022
sharman tanya schuler
5.3%
5,943,881
SC 13D/A
Dec 30, 2021
schuler tino hans
4.3%
4,829,019
SC 13D/A
Dec 30, 2021
schuler henri george
8.2%
9,207,779
SC 13D/A
Nov 24, 2021
feinberg larry n
4.95%
5,547,104
SC 13D/A

Recent SEC filings of Aspira Women's Health Inc.

View All Filings
Date Filed Form Type Document
Feb 20, 2024
4
Insider Trading
Feb 14, 2024
4
Insider Trading
Feb 14, 2024
4
Insider Trading
Feb 07, 2024
D
D
Jan 30, 2024
4
Insider Trading
Jan 26, 2024
424B5
Prospectus Filed
Jan 26, 2024
8-K/A
Current Report
Jan 26, 2024
S-8
Employee Benefits Plan
Jan 25, 2024
8-K
Current Report
Jan 05, 2024
8-K
Current Report

Peers (Alternatives to Aspira Women's Health Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
186.9B
27.6B
10.99% -3.42%
39.24
6.77
-8.71% -33.92%
47.5B
3.7B
3.78% 14.37%
56.17
12.97
8.72% 24.44%
38.7B
6.8B
3.29% -11.61%
31.19
5.66
-0.22% -1.12%
14.0B
9.3B
-8.35% -14.36%
16.44
1.52
-6.38% -9.73%
12.7B
4.1B
15.83% -0.20%
26.72
3.07
3.86% -2.39%
11.1B
2.5B
-9.16% -4.81%
-54.17
4.42
19.93% 67.26%
MID-CAP
12.1B
1.9B
36.59% 75.21%
42.82
6.42
29.17% 15.26%
8.5B
988.7M
14.98% 63.69%
-17.12
8.65
27.41% 8.51%
3.7B
918.7M
-2.97% -10.18%
316.38
4.06
45.66% 172.57%
2.7B
563.9M
-7.36% -19.90%
-5.69
4.84
25.45% 26.76%
SMALL-CAP
447.4M
297.1M
-26.16% -46.86%
-4.94
1.51
-6.74% -21.60%
85.7M
21.4M
29.35% -91.67%
-0.75
4
-8.80% -39.66%
45.6M
9.2M
-1.43% -37.11%
-2.51
4.97
16.43% 46.89%
9.1M
13.4M
6.67% -61.68%
-0.91
0.68
-26.43% -20.54%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Aspira Women's Health Inc. News

Latest updates
The Globe and Mail15 Feb 202408:13 am
CNN12 Feb 202412:34 pm
InvestorsObserver24 Jan 202408:00 am
Securities.io9 months ago

Aspira Women's Health Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-11.0%2,2172,4912,3162,1532,0722,0661,8931,8511,6661,7991,4961,4461,2397461,2201,3081,2851,142803922774
Gross Profit-15.7%1,3071,5501,1911,2401,1569669611,014749696603231432153420516336234109169-4.00
Operating Expenses-7.6%5,4235,8716,9606,3319,7369,18610,2089,96010,4408,7686,4896,3054,7133,9794,2203,9204,1864,5393,8282,9932,639
  S&GA Expenses-4.0%1,7021,7722,5622,8883,9503,5804,4974,8775,0834,0183,1082,8432,1521,7332,1152,0762,4252,7802,3641,5961,343
  R&D Expenses44.0%9986931,2311,0022,1571,4101,3481,4531,5181,471872734595380395244340225209125129
EBITDA Margin1.4%-2.05*-2.08*-2.18*-2.30*-2.40*-2.53*-2.62*-2.77*-2.94*-3.15*-3.82*-4.05*-4.18*--------
Interest Expenses50.0%12.008.0026.0027.0018.00-10.00-18.00-13.00-14.003.00-24.00-4.005.001.008.0020.0034.00-2.007.003.00-6.00
EBT Margin1.6%-2.08*-2.12*-2.22*-2.34*-2.43*-2.56*-2.65*-2.81*-2.98*-3.20*-3.88*-4.11*-4.24*--------
Net Income-103.1%-4,706-2,317-6,578-4,591-7,783-8,243-9,268-8,961-9,707-7,074-5,920-6,081-4,287-3,831-3,706-3,387-3,820-4,314-3,716-2,820-2,652
Net Income Margin15.8%-1.98*-2.35*-3.16*-3.65*-4.35*-4.84*-4.86*-4.65*-4.49*-3.91*-4.08*-3.85*-3.37*--------
Free Cashflow-2.7%3,3213,413-5,714-7,150-7,568-6,327-10,255-7,679-8,019-6,585-5,296-4,979-3,211--------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets12.2%8,6627,72011,49617,37323,94224,01630,86141,07948,04755,82962,29719,60521,26513,09110,35313,82816,53318,1528,25411,40813,474
  Current Assets10.3%7,5726,86210,52816,30922,97622,95629,80040,00547,18854,90761,37318,60320,25112,6909,98613,41016,05017,5657,57610,78812,773
    Cash Equivalents20.1%5,1004,2467,53513,30620,55120,48026,85537,43044,87052,99359,36916,63118,83610,9358,13211,70314,63616,1796,1749,36011,760
  Inventory10.7%30127230231628019118917413710171.0030.0045.0066.0063.0025.0029.0090.0098.0092.00115
  Net PPE-15.3%221261305368417438480464498546533583593360318353399472531608701
Liabilities13.0%9,3218,24810,66910,39412,7649,8949,11710,9079,5438,9919,9729,8866,7155,8245,0515,0904,7064,7864,6174,2563,764
  Current Liabilities-3.9%5,1625,3745,9115,5277,2977,0446,1397,8406,4095,7916,1486,0004,6154,1993,9853,9783,5373,5613,3362,9642,424
  Short Term Borrowings-74.8%77.00306535764-260519779-204408611476587194303192191190189188
  Long Term Debt-8.8%1,2171,3342,2042,3152,4262,5362,6462,7182,7682,8182,7183,4771,6781,6151,0501,0991,1481,1961,2441,2921,340
    LT Debt, Current45.9%378259442403343283223201200199201645---193-----
    LT Debt, Non Current-8.8%1,2171,3342,2042,3152,4262,5362,6462,7182,7682,8182,7183,4771,6781,6151,0501,0991,1481,1961,2441,2921,340
Shareholder's Equity0.9%514,544509,9718276,97911,17814,12221,74430,17238,50446,83852,3259,71914,5507,2675,3028,73811,82713,3663,6377,1529,710
  Retained Earnings-1.6%-515,214-507,282-504,965-501,613-497,022-489,239-480,996-471,728-462,767-453,060-445,986-440,066-433,985-429,698-425,867-422,161-418,774-414,954-410,640-406,924-404,104
  Additional Paid-In Capital1.5%514,544506,745505,784508,584508,192503,249502,628501,893501,159499,786498,199449,680448,431436,864431,072430,802430,504428,226414,202414,001413,739
Shares Outstanding21.4%10,2878,4738,3308,3068,2967,4797,4767,4767,3947,4647,2446,9756,880--------
Float------50,184---477,546---290,268---47,232---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-2.8%3,3213,417-5,706-7,076-7,515-6,304-10,173-7,649-8,001-6,490-5,255-4,756-3,067-3,410-3,501-2,871-3,442-3,544-3,108-2,298-2,293
  Share Based Compensation39.5%6814881334205466108385901,1781,282489427411441269300296413184262296
Cashflow From Investing100.0%--4.00-8.00-74.00-53.00-23.00-82.00-30.00-18.00-95.00-41.00-223-144-100-23.00-12.00-39.00-34.00-48.00-55.00-24.00
Cashflow From Financing3016.4%4,176134-55.00-94.007,639-48.00-70.00-11.0014620948,0342,77411,1126,313-47.00-50.001,93813,583-30.00-47.00-58.00

AWH Income Statement

2023-09-30
Condensed Consolidated Statements Of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:        
Revenue$ 2,217  $ 2,072  $ 7,024$ 6,031
Cost of revenue:        
Cost of revenue910  916  2,9812,948
Gross profit1,307  1,156  4,0433,083
Operating expenses:        
Research and development998  2,157  2,9584,915
Sales and marketing1,702  3,950  6,06912,027
General and administrative2,723  3,629  9,73312,188
Total operating expenses5,423  9,736  18,76029,130
Loss from operations(4,116)  (8,580)  (14,717)(26,047)
Change in fair value of warrant liabilities(1,201)  1,236  (233)1,236
Interest income (expense), net12  18  46(10)
Other income (expense), net599  (457)  1,303(473)
Net loss$ (4,706)$ (2,317)$ (6,578)$ (7,783)$ (8,243)$ (9,268)$ (13,601)$ (25,294)
Net loss per share - basic$ (0.48)  $ (1.00)  $ (1.54)$ (3.33)
Net loss per share - diluted$ (0.48)  $ (1.00)  $ (1.54)$ (3.33)
Weighted average common shares used to compute basic net loss per common share9,776,436  7,807,876  8,838,3427,590,872
Weighted average common shares used to compute diluted net loss per common share9,776,436  7,807,876  8,838,3427,590,872
Product [Member]        
Revenue:        
Revenue$ 2,217  $ 2,037  $ 7,023$ 5,890
Cost of revenue:        
Cost of revenue$ 910  875  2,9812,768
Genetics [Member]        
Revenue:        
Revenue   35  $ 1141
Cost of revenue:        
Cost of revenue   $ 41   $ 180

AWH Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Current assets:        
Cash and cash equivalents$ 5,100  $ 13,306$ 20,551   
Accounts receivable, net of allowance of $35 and $9, at September 30, 2023 and December 31, 2022, respectively1,590  1,2451,201   
Prepaid expenses and other current assets581  1,442944   
Inventories301  316280   
Total current assets7,572  16,30922,976   
Property and equipment, net221  368417   
Right-of-use assets600  282299   
Restricted cash256  251250   
Other assets13  163    
Total assets8,662  17,37323,942   
Current liabilities:        
Accounts payable1,382  8811,893   
Accrued liabilities3,089  3,4024,988   
Current portion of long-term debt378  403343   
Short-term debt77  764    
Current maturities of lease liabilities236  7773   
Total current liabilities5,162  5,5277,297   
Non-current liabilities:        
Long-term debt1,217  2,3152,426   
Non-current maturities of lease liabilities429  272293   
Warrant liabilities2,513  2,2802,748   
Total liabilities9,321  10,39412,764   
Commitments and contingencies (Note 4)     
Stockholders’ (deficit) equity:        
Common stock, par value $0.001 per share, 200,000,000 and 150,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 10,287,182 and 8,306,326 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively11  88   
Additional paid-in capital514,544  508,584508,192   
Accumulated deficit(515,214)  (501,613)(497,022)   
Total stockholders’ (deficit) equity(659)$ (528)$ 8276,97911,178$ 14,122$ 21,744$ 30,172
Total liabilities and stockholders’ (deficit) equity$ 8,662  $ 17,373$ 23,942   
AWH
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
 CEO
 WEBSITEaspirawh.com
 EMPLOYEES85

Aspira Women's Health Inc. Frequently Asked Questions


What is the ticker symbol for Aspira Women's Health Inc.? What does AWH stand for in stocks?

AWH is the stock ticker symbol of Aspira Women's Health Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aspira Women's Health Inc. (AWH)?

As of Thu Feb 22 2024, market cap of Aspira Women's Health Inc. is 45.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AWH stock?

You can check AWH's fair value in chart for subscribers.

What is the fair value of AWH stock?

You can check AWH's fair value in chart for subscribers. The fair value of Aspira Women's Health Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aspira Women's Health Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AWH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aspira Women's Health Inc. a good stock to buy?

The fair value guage provides a quick view whether AWH is over valued or under valued. Whether Aspira Women's Health Inc. is cheap or expensive depends on the assumptions which impact Aspira Women's Health Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AWH.

What is Aspira Women's Health Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, AWH's PE ratio (Price to Earnings) is -2.51 and Price to Sales (PS) ratio is 4.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AWH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aspira Women's Health Inc.'s stock?

In the past 10 years, Aspira Women's Health Inc. has provided -0.2 (multiply by 100 for percentage) rate of return.